Trial Profile
A Pilot, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety, Tolerability and Efficacy of 40 mg QD and 80 mg QD ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Feb 2013
Price :
$35
*
At a glance
- Drugs Pozanicline (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- 27 Jan 2010 Actual patient number changed from 150 to 160 as reported by ClinicalTrials.gov.
- 27 Jan 2010 Actual patient number changed from 150 to 160 as reported by ClinicalTrials.gov.
- 10 Apr 2008 New trial record.